CMXHF News and Press, Csl Ltd From 12/07/22

Summary Recent approval of Hemgenix therapy creates alpha opportunity. Market has responded swiftly and we see upside targets of $31.5 and then $49. The Hemophilia B treatment market is complex and in need of a remedial breakthrough, forming part of our buy thesis. Rate buy. ...

The superior reactogenicity profile of Novavax's Nuvaxovid vaccine could make it the preferred choice amongst some in an endemic COVID environment. The company's other promising vaccine, NanoFlu, is being overlooked due to the market's focus on COVID. The recent decline in the NVA...

The Swiss Agency for Therapeutic Products (Swissmedic) approved Cara Therapeutics ( NASDAQ: CARA ) and Vifor Fresenius Medical Care Renal Pharma's Kapruvia (difelikefalin) to treat moderate-to-severe pruritus (itching) associated with chronic kidney disease ...

Vifor Fresenius Medical Care Renal Pharma said that England's National Institute for Health and Care Excellence (NICE) recommended Tavneos in combination with a rituximab or cyclophosphamide regimen to treat adult patients with severe, active granulomatosis polyangiitis (GPA)...

CSL Limited (CSLLY) Q4 2022 Earnings Conference Call August 16, 2022 21:00 ET Company Participants Mark Dehring - Head, Investor Relations Paul Perreault - Chief Executive Officer Joy Linton - Chief Financial Officer Paul McKenzie - Chief Operating Officer ...

The following slide deck was published by CSL Limited in conjunction with their 2022 Q4 earnings call. For further details see: CSL Limited 2022 Q4 - Results - Earnings Call Presentation

The Project $1M portfolio has had a major leg down in the first half of 2022. Relatively good performances from Visa and Mastercard were unable to offset large declines in Sea Ltd and Meta. While share prices are done, core business performance from many companies that have report...

Seqirus, a unit of Australian biotech CSL Limited (OTCPK:CSLLY) (OTCPK:CMXHF), announced that a group of independent experts of the U.S. CDC added its Fluad Quadrivalent shot as a preferentially recommended seasonal influenza vaccine for those aged 65 years and older. The decision of the CDC&...

Polen Capital is a high-conviction growth investment manager. We scour the globe in search of the highest quality, sustainable companies to invest in. Over the first quarter of 2022, the Polen International Growth Composite Portfolio returned -13.94% gross and -14.17% net of fees, res...

CSL's (OTCPK:CSLLY) unit CSL Behring reported provisional results of its tender offer to acquire all publicly held shares of Vifor Pharma (OTCPK:GNHAY) for $179.25/ share in a deal valued at ~$11.7B. CSL's participation at the end of the additional acceptance period on March 22 was a total of...